CTS: Histology Can Drive Treatment of Lung Cancer with Pemetrexed
Pathologic examination of non-small-cell lung cancer appears to give clinicians clues for refining treatment choices, researchers said here.
“We are entering the era of individualized medicine in lung cancer,” said Chandra P. Belani, M.D., of the Pennsylvania State University Hershey Medical Center, at the Chicago Multidisciplinary Symposium in Thoracic Oncology.
This entry was posted on Friday, November 14th, 2008 at 5:11 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.